Beskrywing

A study by StrategyHelix indicates that the global biological therapies for cancer market is expected to increase by US$ 50.0 miljard van 2022 aan 2028, 'n CAGR van 8.2% gedurende die voorspellingsperiode.

Die verslag verskaf up-to-date markgrootte data vir tydperk 2018-2021 en voorspel tot 2028 covering key market aspects like sales value for biological therapies for cancer. The global biological therapies for cancer market is segmented on the basis of product, en streek. Gebaseer op produk, the global biological therapies for cancer market is categorized into CAR T-cell therapies, monoclonal antibodies, entstowwe. The monoclonal antibodies segment held the largest share of the global biological therapies for cancer market in 2021 and is anticipated to hold its share during the forecast period. In terms of geography, the global biological therapies for cancer market has been segmented into Asia Pacific, Europa, Noord-Amerika, Rest of the World (RoW). Globally, North America made up the largest share of the biological therapies for cancer market.

The global biological therapies for cancer market is highly competitive. Some of the leading companies operating in the market are Amgen Inc., AstraZeneca plc, Bristol-Myers Squibb Company (BMS), Eli Lilly and Company, F. Hoffmann-La Roche AG, Genmab A/S, Gilead Sciences Inc., GlaxoSmithKline plc (GSK), Janssen Pharmaceuticals Inc., Merck KGaA, Novartis International AG, Pfizer Inc.

Die verslag is 'n waardevolle hulpbron vir maatskappye en organisasies wat in hierdie bedryf aktief is. It provides a cohesive picture of the biological therapies for cancer market to help drive informed decision making for industry executives, beleidmakers, akademies, en ontleders.

Verslag Omvang

Produk: CAR T-cell therapies, monoclonal antibodies, entstowwe
Streek: Asiatiese Stille-Oseaan, Europa, Noord-Amerika, Rest of the World (RoW)
Jare oorweeg: hierdie verslag dek die tydperk 2018 aan 2028

Sleutelvoordele vir belanghebbendes

– Get a comprehensive picture of the global biological therapies for cancer market
– Bepaal groeisektore en -neigings vir belegging

INHOUDSOPGAWE

Deel 1. Inleiding
– Omvang van die studie
– Studietydperk
– Geografiese omvang
– Navorsingsmetodologie
Deel 2. Biological therapies for cancer market overview
Deel 3. Market breakdown by product
– CAR T-cell therapies
– Monoclonal antibodies
– Vaccines
Deel 4. Market breakdown by region
– Asiatiese Stille-Oseaan
– Europa
– Noord-Amerika
– Rest of the World (RoW)
Deel 5. Sleutel maatskappye
– Amgen Inc.
– AstraZeneca plc
– Bristol-Myers Squibb Company (BMS)
– Eli Lilly and Company
– F. Hoffmann-La Roche AG
– Genmab A/S
– Gilead Sciences, Inc.
– GlaxoSmithKline plc (GSK)
– Janssen Pharmaceuticals, Inc.
– Merck KGaA
– Novartis International AG
– Pfizer Inc.
Oor StrategyHelix
Vrywaring